Johnson & Johnson Services, Inc.

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study (2024) Taylor PC, Schett G, Huizinga TW, Wang Q, Ibrahim F, Zhou B, Liva SG, et al. Journal article Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis (2024) Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, Seridi L, et al. Journal article Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial (2024) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty SD, et al. Journal article Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article Impact of a digital surgical workflow including Digital Device Briefing Tool on morbidity and mortality in a patient population undergoing primary stapled colorectal anastomosis for benign or malignant colorectal disease: protocol for a multicentre prospective cohort study (2023) Lauscher J, Beyer K, Hellinger A, Croner RS, Ridwelski K, Krautz C, Lim C, et al. Journal article Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article, Erratum Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naive Adults with PsA (2022) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty S, et al. Conference contribution IMMUNOLOGICAL DIFFERENCES BETWEEN PSA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS (2022) Siebert S, Coates L, Schett G, Raychaudhuri SP, Chen W, Gao S, Chakravarty SD, et al. Conference contribution GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL (2022) Marzo-Ortega H, Theander E, Neuhold M, Bergmans P, Shawi M, Perate M, Contre C, et al. Conference contribution Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic (2017) O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, et al. Journal article